{
 "companyname": "ENZON PHARMACEUTICALS INC",
 "symbol": "ENZN",
 "description": "Biological Products, Except Diagnostic Substances",
 "quarters": [
  {
   "cik": "0000727510",
   "companyname": "ENZON PHARMACEUTICALS INC",
   "entityid": 9657,
   "primaryexchange": "Nasdaq Global Market",
   "primarysymbol": "ENZN",
   "siccode": "2836",
   "sicdescription": "Biological Products, Except Diagnostic Substances",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "11/6/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "9/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 3,
   "dcn": "0001144204-15-063360",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": null,
   "changeincurrentliabilities": null,
   "changeininventories": null,
   "dividendspaid": -22091000,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": null,
   "cashfromfinancingactivities": -22091000,
   "cashfrominvestingactivities": 0,
   "cashfromoperatingactivities": 3353000,
   "cfdepreciationamortization": null,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": null,
   "netchangeincash": -18738000,
   "totaladjustments": 5167000,
   "ebit": -926000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 3839000,
   "incomebeforetaxes": -926000,
   "interestexpense": null,
   "netincome": -1814000,
   "netincomeapplicabletocommon": -1814000,
   "researchdevelopmentexpense": null,
   "totalrevenue": 3839000,
   "sellinggeneraladministrativeexpenses": 213000,
   "commonstock": 441000,
   "deferredcharges": null,
   "cashandcashequivalents": 20255000,
   "cashcashequivalentsandshortterminvestments": 20255000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": null,
   "othercurrentassets": 304000,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": 0,
   "preferredstock": 0,
   "propertyplantequipmentnet": null,
   "retainedearnings": -91763000,
   "totalassets": 21407000,
   "totalcurrentassets": 20559000,
   "totalcurrentliabilities": 4761000,
   "totalliabilities": 4761000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 16646000,
   "treasurystock": null
  },
  {
   "cik": "0000727510",
   "companyname": "ENZON PHARMACEUTICALS INC",
   "entityid": 9657,
   "primaryexchange": "Nasdaq Global Market",
   "primarysymbol": "ENZN",
   "siccode": "2836",
   "sicdescription": "Biological Products, Except Diagnostic Substances",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "8/7/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "6/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 2,
   "dcn": "0001144204-15-047327",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": null,
   "changeincurrentliabilities": null,
   "changeininventories": null,
   "dividendspaid": 0,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": null,
   "cashfromfinancingactivities": 0,
   "cashfrominvestingactivities": 0,
   "cashfromoperatingactivities": 4189000,
   "cfdepreciationamortization": null,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": null,
   "netchangeincash": 4189000,
   "totaladjustments": 408000,
   "ebit": 4676000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 5192000,
   "incomebeforetaxes": 4676000,
   "interestexpense": null,
   "netincome": 3782000,
   "netincomeapplicabletocommon": 3782000,
   "researchdevelopmentexpense": null,
   "totalrevenue": 5192000,
   "sellinggeneraladministrativeexpenses": 516000,
   "commonstock": 441000,
   "deferredcharges": null,
   "cashandcashequivalents": 38993000,
   "cashcashequivalentsandshortterminvestments": 38993000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": null,
   "othercurrentassets": 613000,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": 322000,
   "preferredstock": 0,
   "propertyplantequipmentnet": null,
   "retainedearnings": -89949000,
   "totalassets": 41288000,
   "totalcurrentassets": 39606000,
   "totalcurrentliabilities": 22506000,
   "totalliabilities": 22828000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 18460000,
   "treasurystock": null
  },
  {
   "cik": "0000727510",
   "companyname": "ENZON PHARMACEUTICALS INC",
   "entityid": 9657,
   "primaryexchange": "Nasdaq Global Market",
   "primarysymbol": "ENZN",
   "siccode": "2836",
   "sicdescription": "Biological Products, Except Diagnostic Substances",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "5/13/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "3/31/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 1,
   "dcn": "0001144204-15-029931",
   "currencycode": "USD",
   "crosscalculated": false,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": null,
   "changeincurrentliabilities": null,
   "changeininventories": null,
   "dividendspaid": -4417000,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": null,
   "cashfromfinancingactivities": -4423000,
   "cashfrominvestingactivities": 0,
   "cashfromoperatingactivities": 4665000,
   "cfdepreciationamortization": null,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": null,
   "netchangeincash": 242000,
   "totaladjustments": -2508000,
   "ebit": 4678000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 5261000,
   "incomebeforetaxes": 4678000,
   "interestexpense": null,
   "netincome": 7173000,
   "netincomeapplicabletocommon": 7173000,
   "researchdevelopmentexpense": null,
   "totalrevenue": 5261000,
   "sellinggeneraladministrativeexpenses": 583000,
   "commonstock": 441000,
   "deferredcharges": null,
   "cashandcashequivalents": 34804000,
   "cashcashequivalentsandshortterminvestments": 34804000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": null,
   "othercurrentassets": 483000,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": 351000,
   "preferredstock": 0,
   "propertyplantequipmentnet": null,
   "retainedearnings": -93730000,
   "totalassets": 37830000,
   "totalcurrentassets": 35287000,
   "totalcurrentliabilities": 709000,
   "totalliabilities": 1060000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 36770000,
   "treasurystock": null
  }
 ]
}